中国P站

Abstract

Liquid biopsy has emerged as a revolutionary technique in cancer diagnostics, offering a non-invasive approach to detect and monitor tumor dynamics through the analysis of circulating tumor DNA (ctDNA), RNA, exosomes, and circulating tumor cells (CTCs). In orthopedic oncology, where traditional biopsy procedures are often invasive, painful, and carry risks of tumor seeding, liquid biopsy presents a promising alternative for real-time tumor profiling, early detection of recurrence, and personalized treatment planning. This article explores the principles of liquid biopsy, its application in the management of bone and soft tissue sarcomas, current limitations, and future directions. By integrating this innovative tool into the multidisciplinary framework of orthopedic oncology, clinicians can enhance diagnostic precision, therapeutic decision-making, and long-term monitoring of patients with musculoskeletal tumors.